Arax Advisory Partners
FATE icon

Arax Advisory Partners’s Fate Therapeutics FATE Stock Holding History

Arax Advisory Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.5K Sell
7,816
-36,506
-82% -$94.4K ﹤0.01% 4070
2026
Q2 		$120K Buy
44,322
+43,557
+5,694% +$80.6K ﹤0.01% 2601
2026
Q1 		$918 Buy
+765
New +$931 ﹤0.01% 3319
2025
Q4 		– Sell
-8,570
Closed -$10.8K – 4229
2025
Q3 		$10.8K Buy
+8,570
New +$9.24K ﹤0.01% 2562
2024
Q4 		– Sell
-102
Closed -$357 – 2523
2024
Q3 		$357 Hold
102
– – ﹤0.01% 2450
2024
Q2 		$335 Buy
+102
New +$447 ﹤0.01% 2382

Other funds holding FATE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Arax Advisory Partners's FATE Position: Q3 2026 in Review

Arax Advisory Partners reduced its Fate Therapeutics (FATE) stake by 82% in Q3 2026, selling an estimated $94.4K and leaving 7,816 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4070.

Arax Advisory Partners first reported a position in FATE in Q2 2024 and has held it in 6 quarters since. The position peaked at $120K in Q2 2026. 101 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Arax Advisory Partners held 7,816 shares of Fate Therapeutics worth $18.5K as of Q3 2026.
  • Arax Advisory Partners sold 36,506 Fate Therapeutics shares in Q3 2026, an estimated $94.4K.
  • Fate Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4070 holding.
  • Arax Advisory Partners first reported a position in Fate Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Fate Therapeutics position peaked at $120K in Q2 2026.
  • 101 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.